Publications

Clinical research | Animal model | Vaccine formulation | Vaccine delivery | Basic research

 

TREOS team has over 250 peer reviewed scientific publication covering vaccine research and clinical trials, and experience in therapeutic vaccine and medical devices development and manufacturing. A selected list is shown here:

 

Clinical research

 

  • Rodriguez B, Asmuth DM, Matining RM, Spritzler J, Jacobson JM, Mailliard RB, Li XD, Martinez AI, Tenorio AR, Lori F, Lisziewicz J, Yesmin S, Rinaldo CR, Pollard Safety, Tolerability, and Immunogenicity of Repeated Doses of DermaVir, a Candidate Therapeutic HIV Vaccine, in HIV-Infected Patients Receiving Combination Antiretroviral Therapy: Results of the ACTG 5176 Trial. J Acquir Immune Defic Syndr. 2013 Dec 1;64(4):351-9. doi: 10.1097/QAI.0b013e3182a99590. PubMed PMID: 24169120.
  • Lisziewicz J, Bakare N, Calarota SA, Bánhegyi D, Szlávik J, Ujhelyi E, Tőke ER, Molnár L, Lisziewicz Z, Autran B, Lori F. Single DermaVir immunization: dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals. PLoS 2012;7(5):e35416. doi: 10.1371/journal.pone.0035416. Epub 2012 May 9. PubMed PMID: 22590502; PubMed Central PMCID: PMC3348904.
  • Lori F, De Forni D, Katabira E, Baev D, Maserati R, Calarota SA, Cahn P, Testori M, Rakhmanova A, Stevens MR. VS411 reduced immune activation and HIV-1 RNA levels in 28 days: randomized proof- of-concept study for antiviral-hyperactivation limiting therapeutics. PLoS One. 2012;7(10):e47485. doi: 10.1371/journal.pone.0047485, 2012 PubMed PMCID: PMC3477169.
  • Gudmundsdotter L, Wahren B, Haller BK, Boberg A, Edbäck U, Bernasconi D, Buttò S, Gaines H, Imami N, Gotch F, Lori F, Lisziewicz J, Sandström E, Hejdeman B. Amplified antigen- specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial. Vaccine. 2011 Jul 26;29(33):5558-66. doi:10.1016/j.vaccine.2011.01.064. Epub 2011 Feb 5. PubMed PMID: 21300092.
  • De Forni D, Stevens MR, and Lori F. Strategies to improve efficacy and safety of a novel class of antiviral hyper-activation-limiting therapeutic agents: the VS411 model in human immunodeficiency virus/acquired immunodeficiency syndrome. British Journal of Pharmacology 161(4):830-43, 2010. PubMed PMCID: PMC2992898.
  • Calarota SA, Foli A, Maserati R, Baldanti F, Paolucci S, Young MA, Tsoukas CM, Lisziewicz J, Lori F. HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. J Immunol. 2008 May 1;180(9):5907-15. PubMed PMID: 18424710.
  • Shepard BD, De Forni D, McNamara DR, Foli A, Rizza SA, Abraham RS, Knutson K, Wettstein PJ, Lori F, and Badley AD. Beneficial Effect of TRAIL on HIV Burden, without Detectable Immune Consequences. PLoS One 3:1-7, 2008. PubMed PMID: 18769477, PMCID:PMC2517653
  • Maserati R, Foli A, Tomasoni L, Sighinolfi L, Maggiolo F, Sacchini D, Di Pietro M, Bertelli D, Tinelli C, and Lori F. Effects of Structured Treatment Interruptions on Metabolilc, Anthrompometric, Immunologic, and Quality of Life Outcomes in HIV-Positive Adults on HAART. Current HIV Research 5:337-43, 2007. PubMed PMID: 17504175.
  • Lori F, Foli A, Groff A, Lova L, Whitman L, Bakare N, Pollard RB, Lisziewicz J. Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic (‘virostatic’) AIDS. 2005 Jul 22;19(11):1173-81. PubMed PMID: 15990570.
  • Lori F, Pollard RB, Whitman L, Bakare N, Blick G, Shalit P, Foli A, Peterson D, Tennenberg A, Schrader S, Rashbaum B, Farthing C, Herman D, Norris D, Greiger P, Frank I, Groff A, Lova L, Asmuth D, Lisziewicz J. Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV AIDS Res Hum Retroviruses. 2005 Apr;21(4):263-72. PubMed PMID: 15943568.
  • Lori F, Kelly LM, Foli A, Lisziewicz J. Safety of hydroxyurea in the treatment of HIV Expert Opin Drug Saf. 2004 Jul;3(4):279-88. Review. PubMed PMID: 15268646.
  • Foli A, Maserati R, Barasolo G, Castelli F, Tomasoni L, Migliorino M, Maggiolo F, Pan A, Paolucci S, Scudeller L, Tinelli C, D’Aquila R, Lisziewicz J, Lori F. Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment Antivir Ther. 2004 Feb;9(1):123-32. PubMed PMID: 15040544.
  • Lori F, Maserati R, Lisziewicz J, Minoli Immune reconstitution and control of HIV. HIV Clin Trials. 2004 May-Jun;5(3):170-82. PubMed PMID: 15248142.
  • Lisziewicz J, Foli A, Wainberg M, Lori F. Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety Drug Saf. 2003;26(9):605-24. Review. PubMed PMID: 12814330.
  • Garcia F, Plana M, Arnedo M, Ortiz GM, Miro JM, Lopalco L, Lori F, Pumarola T, Gallart T, Gatell JM. A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study. 3;17(1): 43-51, 2003. PubMed PMID:12478068
  • Lori F, Foli A, Lisziewicz J. Structured treatment interruptions as a potential alternative therapeutic regimen for HIV-infected patients: a review of recent clinical data and future J Antimicrob Chemother. 2002 Aug;50(2):155-60. Review. PubMed PMID: 12161394.
  • Foli A, Seminari E, Ravot E, Lisziewicz J, Lori F. Role of hydroxyurea during structured treatment J Biol Regul Homeost Agents. 2002 Jan-Mar;16(1):64-8. PubMed PMID: 12003177.
  • Lori F, Foli A, Maserati R, Seminari E, Xu J, Whitman L, Ravot E, Alberici F, Lopalco L, Lisziewicz J. Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell HIV Clin Trials. 2002 Mar-Apr;3(2):115-24. PubMed PMID: 11976989.
  • Xu J, Whitman L, Lori F, Lisziewicz J. Methods of using interleukin 2 to enhance HIV- specific immune AIDS Res Hum Retroviruses. 2002 Mar 1;18(4):289-93. PubMed PMID: 11860676.
  • Ravot E, Tambussi G, Jessen H, Tinelli C, Lazzarin A, Lisziewicz J, Lori F. Effects of hydroxyurea on T cell count changes during primary HIV AIDS. 2000 Mar 31;14(5):619-22. PubMed PMID: 10780728.
  • Lori F, Maserati R, Foli A, Seminari E, Timpone J, Lisziewicz J. Structured treatment interruptions to control HIV-1 Lancet. 2000 Jan 22;355(9200):287-8. PubMed PMID: 10675080.
  • Lori F, Jessen H, Lieberman J, Finzi D, Rosenberg E, Tinelli C, Walker B, Siliciano RF, Lisziewicz J. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral J Infect Dis. 1999 Dec;180(6):1827-32. PubMed PMID: 10558937.
  • Seminari E, Lisziewicz J, Tinelli C, Foli A, Lori F, Maserati Hydroxyurea toxicity combined with didanosine (ddl) in HIV-1-seropositive asymptomatic individuals. Int J Clin Pharmacol Ther. 1999 Oct;37(10):514-8. PubMed PMID: 10543320.
  • Lori F, Rosenberg E, Lieberman J, Foli A, Maserati R, Seminari E, Alberici F, Walker B, Lisziewicz J. Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune AIDS Res Hum Retroviruses. 1999 Oct 10;15(15):1333-8. PubMed PMID: 10515148.
  • Lieberman J, Trimble LA, Friedman RS, Lisziewicz J, Lori F, Shankar P, Jessen Expansion of CD57 and CD62L-CD45RA+ CD8 T lymphocytes correlates with reduced viral plasma RNA after primary HIV infection. AIDS. 1999 May 28;13(8):891-9. PubMed PMID: 10371169.
  • Lisziewicz J, Rosenberg E, Lieberman J, Jessen H, Lopalco L, Siliciano R, Walker B, Lori F. Control of HIV despite the discontinuation of antiretroviral N Engl J Med. 1999 May 27;340(21):1683-4. PubMed PMID: 10348681.
  • Lori F, Jessen H, Lieberman J, Clerici M, Tinelli C, Lisziewicz J. Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir). AIDS Res Hum 1999 May 1;15(7):619-24. PubMed PMID: 10331440.
  • Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999 May;5(5):512-7. PubMed PMID: 10229227.
  • Boyer PL, Lisziewicz J, Lori F, Hughes Analysis of amino insertion mutations in the fingers subdomain of HIV-1 reverse transcriptase. J Mol Biol. 1999 Mar 5;286(4):995-1008. PubMed PMID: 10047477.
  • Lisziewicz J, Jessen H, Finzi D, Siliciano RF, Lori F. HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease Lancet. 1998 Jul 18;352(9123):199-200. PubMed PMID: 9683211.
  • Foli A, Maserati R, Minoli L, Wainberg MA, Gallo RC, Lisziewicz J, Lori F. Therapeutic advantage of hydroxyurea and didanosine combination therapy in patients previously treated with AIDS. 1998 Jun 18;12(9):1113-4. PubMed PMID: 9662215.
  • Lori F, Malykh AG, Foli A, Maserati R, De Antoni A, Minoli L, Padrini D, Degli Antoni A, Barchi E, Jessen H, Wainberg MA, Gallo RC, Lisziewicz J. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 AIDS Res Hum Retroviruses. 1997 Nov 1;13(16):1403-9. PubMed PMID: 9359660.
  • De Antoni A, Foli A, Lisziewicz J, Lori F. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination J Infect Dis. 1997 Oct;176(4):899-903. PubMed PMID: 9333147.
  • Lori F, Jessen H, Foli A, Lisziewicz J, Matteo Long-term suppression of HIV-1 by hydroxyurea and didanosine. JAMA. 1997 May 14;277(18):1437-8. PubMed PMID: 9145714.
  • Foli A, Lori F, Maserati R, Tinelli C, Minoli L, Lisziewicz J. Hydroxyurea and didanosine is a more potent combination than hydroxyurea and Antivir Ther. 1997 Jan;2(1):31-8. PubMed PMID: 11322264.
  • Villani P, Maserati R, Regazzi-Bonora M, Giacchino R, and Lori F. Pharmacokinetics of Hydroxyurea in Patients Infected with Human Immunodeficiency Virus Type I. Clin. Pharmacol. 36(2): 117-121, 1996. PubMed PMID: 8852387.
  • Lisziewicz J, Sun D, Lisziewicz A, Gallo Antitat gene therapy: a candidate for late-stage AIDS patients. Gene Ther. 1995 May;2(3):218-22. PubMed PMID: 7614253.

 

Animal model

 

  • Verstrepen BE, Oostermeijer H, Fagrouch Z, van Heteren M, Niphuis H, Haaksma T, Kondova I, Bogers WM, de Filette M, Sanders N, Stertman L, Magnusson S, Lőrincz O,Lisziewicz J, Barzon L, Palù G, Diamond MS, Chabierski S, Ulbert S, Verschoor EJ: Vaccine-induced protection of rhesus macaques against plasma viremia after intradermal infection with a European lineage 1 strain of West Nile virus. PLoS One. 2014 Nov 13;9(11):e112568. doi: 10.1371/journal.pone.0112568. PubMed PMID: 25392925.
  • De Filette M, Soehle S, Ulbert S, Richner J, Diamond MS, Sinigaglia A, Barzon L, Roels S, Lisziewicz J, Lőrincz O, Sanders NN: Vaccination of mice using the West Nile virus E- protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal PLoS One, 2014, in press.
  • Garaczi E, Szabó K, Francziszti L, Csiszovszki Z, Lőrincz O, Tőke ER, Molnár L, Bitai T, Jánossy T, Bata-Csörgő Z, Kemény L, Lisziewicz J. DermAll nanomedicine for allergen- specific Nanomedicine. 2013 Nov;9(8):1245-54. doi: 10.1016/j.nano.2013.05.011. Epub 2013 Jun 6. PubMed PMID: 23747740.
  • Calarota SA, Dai A, Trocio JN, Weiner DB, Lori F, Lisziewicz J. IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine. 2008 Sep 19;26(40):5188-95. doi: 10.1016/j.vaccine.2008.03.067. Epub 2008 Apr 14. PubMed PMID: 18462844; PubMed Central PMCID: PMC2582635.
  • Cristillo AD, Lisziewicz J, He L, Lori F, Galmin L, Trocio JN, Unangst T, Whitman L, Hudacik L, Bakare N, Whitney S, Restrepo S, Suschak J, Ferrari MG, Chung HK, Kalyanaraman VS, Markham P, Pal HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3. Virology. 2007 Sep 15;366(1):197-211. Epub 2007 May 11. PubMed PMID: 17499328.
  • Calarota SA, Weiner DB, Lori F, Lisziewicz J. Induction of HIV-specific memory T-cell responses by topical DermaVir vaccine. 2007 Apr 20;25(16):3070-4. Epub 2007 Jan 22. PubMed PMID: 17292518.
  • Lisziewicz J, Trocio J, Whitman L, Varga G, Xu J, Bakare N, Erbacher P, Fox C, Woodward R, Markham P, Arya S, Behr JP, Lori F. DermaVir: a novel topical vaccine for HIV/AIDS. J Invest 2005 Jan;124(1):160-9. PubMed PMID: 15654970.
  • Lisziewicz J, Trocio J, Xu J, Whitman L, Ryder A, Bakare N, Lewis MG, Wagner W, Pistorio A, Arya S, Lori F. Control of viral rebound through therapeutic immunization with AIDS. 2005 Jan 3;19(1):35-43. PubMed PMID: 15627031.
  • Richardson MW, Sverstiuk AE, Silvera P, Greenhouse J, Lisziewicz J, Lori F, Khalili K, Lewis MG, Rappaport T-cell receptor excision circles (TREC) in SHIV 89.6p and SIVmac251 models of HIV-1 infection. DNA Cell Biol. 2004 Jan;23(1):1-13. PubMed PMID: 14965468.
  • Lisziewicz J, Gabrilovich DI, Varga G, Xu J, Greenberg PD, Arya SK, Bosch M, Behr JP, Lori F. Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic J Virol. 2001 Aug;75(16):7621-8. PubMed PMID: 11462034; PubMed Central PMCID: PMC114997.
  • Lori F, Lewis MG, Xu J, Varga G, Zinn DE Jr, Crabbs C, Wagner W, Greenhouse J, Silvera P, Yalley-Ogunro J, Tinelli C, Lisziewicz J. Control of SIV rebound through structured treatment interruptions during early Science. 2000 Nov 24;290(5496):1591-3. PubMed PMID: 11090360.
  • Rosenzweig M, Marks DF, Hempel D, Lisziewicz J, Johnson Transduction of CD34+ hematopoietic progenitor cells with an antitat gene protects T-cell and macrophage progeny from AIDS virus infection. J Virol. 1997 Apr;71(4):2740-6. PubMed PMID: 9060627; PubMed Central PMCID: PMC191396.
  • Lori F, Gallo RC, Malykh A, Cara A, Romano J, Markham P: Didanosine but not High Doses of Hydroxyurea Rescue Pigtailed Macaque from a Lethal Dose of SIVsmmpbj14. AIDS Res. Hum. Retr. 13(13): 1083-88, 1997. PubMed PMID: 9282812

 

Vaccine formulation

 

  • Lisziewicz J, Tőke ER. Nanomedicine applications towards the cure of HIV. 2013 Jan;9(1):28-38. doi: 10.1016/j.nano.2012.05.012. Epub 2012 May 30. Review. PubMed PMID: 22659241.
  • Lőrincz O, Tőke ER, Somogyi E, Horkay F, Chandran PL, Douglas JF, Szebeni J, Lisziewicz J. Structure and biological activity of pathogen-like synthetic Nanomedicine. 2012 May;8(4):497-506. doi:10.1016/j.nano.2011.07.013. Epub 2011 Aug 10. PubMed PMID: 21839051; PubMedCentral PMCID: PMC3274662.
  • Lori F. DermaVir: a plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS. Expert Rev Vaccines. 10(10):1371-84, 2011 PubMed PMID:21988301
  • Tőke ER, Lőrincz O, Somogyi E, Lisziewicz J. Rational development of a stable liquid formulation for nanomedicine products. Int J Pharm. 2010 Jun 15;392(1-2):261-7. doi: 10.1016/j.ijpharm.2010.03.048. Epub 2010 Mar 25. PubMed PMID: 20347027.
  • Lori F, Weiner DB, Calarota SA, Kelly LM, Lisziewicz J. Cytokine-adjuvanted HIV-DNA vaccination Springer Semin Immunopathol. 2006 Nov;28(3):231-8. Epub 2006 Oct 20. Review. PubMed PMID: 17053912.
  • Lori F, Trocio J, Bakare N, Kelly LM, Lisziewicz J. DermaVir, a novel HIV immunisation Vaccine. 2005 Mar 18;23(17-18):2030-4. PubMed PMID: 15755566.

 

Vaccine delivery

 

  • Kolonics A, Csiszovszki Z, Tőke ER, Lőrincz O, Haluszka D, Szipőcs R.: In vivo study of targeted nanomedicine delivery into Langerhans cells by multiphoton laser scanning microscopy. Experimental Dermatology, 2014. 23(8):596-605. PubMed PMID: 24903756.
  • Tőke ER, Lőrincz O, Csiszovszki Zs, Somogyi E, Felföldi G, Molnár L, Szipőcs R, Kolonics A, Malissen B, Lori F, Trocio J, Bakare N, Horkay F, Romani N, Tripp CH, Stoitzner P and Lisziewicz J: Exploitation of Langerhans cells for in vivo DNA vaccine delivery into the lymph nodes. Gene Therapy, 2014. Jun;21(6):566-74. PubMed PMID: 24694539.
  • Somogyi E, Xu J, Gudics A, Tóth J, Kovács AL, Lori F, Lisziewicz J. A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP+) mimicking naturally occurring HIV. Vaccine. 2011 Jan 17;29(4):744-53. doi: 10.1016/j.vaccine.2010.11.019. Epub 2010 Nov 23. PubMed PMID: 21109034.
  • Lisziewicz J, Calarota SA, Lori F. The potential of topical DNA vaccines adjuvanted by cytokines. Expert Opin Biol Ther. 2007 Oct;7(10):1563-74. Review. PubMed PMID: 17916048.
  • Lori F, Calarota SA, Lisziewicz J. Nanochemistry-based immunotherapy for HIV-1. Curr Med 2007;14(18):1911-9. Review. PubMed PMID: 17691933.
  • Lisziewicz J, Kelly L, Lori F. Topical DermaVir vaccine targeting dendritic Curr Drug Deliv. 2006 Jan;3(1):83-8. PubMed PMID: 16472097.
  • Lori F, Kelly LM, Lisziewicz J. APC-targeted immunization for the treatment of HIV-1. Expert Rev 2004 Aug;3(4 Suppl):S189-98. Review. PubMed PMID: 15285717.
  • Ravot E, Comolli G, Lori F, Lisziewicz J. High efficiency lentiviral gene delivery in non- dividing cells by deoxynucleoside J Gene Med. 2002 Mar-Apr;4(2):161-9. PubMed PMID: 11933217.

 

Basic research

 

  • Chandran PL, Dimitriadis EK,Lisziewicz J, Speransky V, Horkay F: DNA nanoparticles with core-shell morphology. Soft Matter. 2014 Oct 14;10(38):7653-60. doi: 10.1039/c4sm00908h. PubMed PMID:
  • Somogyi E, Lisziewicz J. HIV vaccine to induce cytotoxic T cells recognizing conserved HIV-1/2-epitopes derived from the most frequent HLA types of the human population. 2013 Aug;5(8):825-8. doi: 10.2217/imt.13.79. PubMed PMID: 23902551.
  • Simon L, Toth J, Molnar L, Agoston DV. MRI analysis of mGluR5 and mGluR1 antagonists, MTEP and R214127 in the cerebral forebrain of awake, conscious rats. Neuroscience Letters. 2011 Nov 14;505(2):155-9 PubMed PMID: 22015763.
  • Hellner G, Tőke ER, Nagy V, Szakács GY, Poppe L. Integrated enzymatic production of specific structured lipid and phytosterol ester compositions. Process Biochemistry, 45, 2010, 1245-1250.
  • Lisziewicz J. Conference scene-active immunotherapeutics forum: meeting highlights. 2009 Sep;1(5):743-8. doi: 10.2217/imt.09.52. PubMed PMID: 20636019.
  • Abbadessa G, Accolla R, Aiuti F, Albini A, Aldovini A, Alfano M, Antonelli G, Bartholomew C, Bentwich Z, Bertazzoni U, Berzofsky JA, Biberfeld P, Boeri E, Buonaguro L, Buonaguro FM, Bukrinsky M, Burny A, Caruso A, Cassol S, Chandra P, Ceccherini-Nelli L, Chieco-Bianchi L, Clerici M, Colombini-Hatch S, de Giuli Morghen C, de Maria A, de Rossi A, Dierich M, Della- Favera R, Dolei A, Douek D, Erfle V, Felber B, Fiorentini S, Franchini G, Gershoni JM, Gotch F, Green P, Greene WC, Hall W, Haseltine W, Jacobson S, Kallings LO, Kalyanaraman VS, Katinger H, Khalili K, Klein G, Klein E, Klotman M, Klotman P, Kotler M, Kurth R, Lafeuillade A, La Placa M, Lewis J, Lillo F, Lisziewicz J, Lomonico A, Lopalco L, Lori F, Lusso P, Macchi B, Malim M, Margolis L, Markham PD, McClure M, Miller N, Mingari MC, Moretta L, Noonan D, O’Brien S, Okamoto T, Pal R, Palese P, Panet A, Pantaleo G, Pavlakis G, Pistello M, Plotkin S, Poli G, Pomerantz R, Radaelli A, Robertguroff M, Roederer M, Sarngadharan MG, Schols D, Secchiero P, Shearer G, Siccardi A, Stevenson M, Svoboda J, Tartaglia J, Torelli G, Tornesello ML, Tschachler E, Vaccarezza M, Vallbracht A, van Lunzen J, Varnier O, Vicenzi E, von Melchner H, Witz I, Zagury D, Zagury JF, Zauli G, Zipeto D. Unsung hero Robert C. Gallo. 2009 Jan 9;323(5911):206-7. doi: 10.1126/science.323.5911.206. PubMed PMID: 19131607.
  • Lisziewicz J. Combining antiretroviral drugs and immune therapies: an approach to achieve clinical benefit after treatment interruption. Curr Opin HIV AIDS. 2008 Mar;3(2):104-11. doi: 10.1097/COH.0b013e3282f50c21. PubMed PMID: 19372950.
  • Csajági CS, Szatzker G, Tőke ER, Ürge L, Darvas F, Poppe L. Enantiomer selective acylation of racemic alcohols by lipases in continous-flow reactors, Tetrahedron: Asymmetry, 19, 2008, 237-246.
  • Szigeti M, Tőke ER, Turóczi MC, Nagy V, Szakács GY, Poppe L. Lipase-catalysed kinetic resolution of 4-aryl- and 4-heteroarylbut-3-en-2-ols, Issue in Honor of Prof Csaba Szántay, Arkivoc, (iii), 2008, 54-65.
  • Lori F. Treating HIV/AIDS by reducing immune system activation: the paradox of immune deficiency and immune hyperactivation. Current Opinion in HIV and AIDS 3:99-103, 2008. PubMed PMID: 19372949.
  • Foli A, Maiocchi MA, Lisziewicz J, Lori F. A checkpoint in the cell cycle progression as a therapeutic target to inhibit HIV replication. J Infect Dis. 2007 Nov 1;196(9):1409-15. Epub 2007 Sep 26. PubMed PMID: 17922407.
  • Lori F, Foli A, Kelly LM, Lisziewicz J. Virostatics: a new class of anti-HIV Curr Med Chem. 2007;14(2):233-41. Review. PubMed PMID: 17266582.
  • Lori F, Foli A, Lisziewicz J. Stopping HAART temporarily in the absence of virus rebound: exploring new HIV treatment options. Curr Opin HIV AIDS. 2007 Jan;2(1):14-20. doi:10.1097/COH.0b013e328011aad6. PubMed PMID: 19372860.
  • Tőke ER, Nagy V, Recseg K, Szakács GY, Poppe L. Production and application of novel sterol esterases from Aspergillus strains by solid state fermentation. Journal of American Oil Chemical Society, 84, 2007, 907-915.
  • Xu JQ, Lori F, Lisziewicz J. CD4+ T cell-mediated presentation of non-infectious HIV-1 virion antigens to HIV-specific CD8+ T Chin Med J (Engl). 2006 Oct 5;119(19):1629-38. PubMed PMID: 17042976.
  • Nagy V, Tőke ER, Keong  LCH,  Szatzker  G,  Ibrahim  D,  Cheomar I, Szakács GY, Poppe L. Kinetic resolutions with novel, highly enantioselective fungal lipases produced by solid state fermentation. Journal of Molecular Catalysis B: Enzymatic, 39, 2006, 141-148.
  • Tőke ER, Kolonits P, Novák L, Poppe L. Lipase mediated enantiomer and diastereomer separation of 2,2’-[1,2-and 1,3-phenylenebis(oxy)]dicyclohexanols, Tetrahedron: Asymmetry, 17, 2006, 2377-2385.
  • Kmecz I, Simándi B, Poppe L, Juvancz Z, Renner K, Bódai V, Tőke ER, Csajági CS, Sawinsky J. Lipase-catalyzed Enantioselective Acylation of 3- Benzyloxypropane-1,2-diol in Supercritical Carbon Dioxide, Biochemical. Engineering. Journal, 28, 2006, 275-280.
  • Lori F: HIV DART 2004 – Frontiers in drug development for antiretroviral therapies. 12-16 December 2004, Montego Bay, Jamaica. IDrugs. Feb;8(2): 97-9, 2005.
  • Lova L, Groff A, Ravot E, Comolli G, Xu J, Whitman L, Lewis M, Foli A, Lisziewicz J, Lori F. Hydroxyurea exerts a cytostatic but not immunosuppressive effect on T AIDS. 2005 Jan 28;19(2):137-44. PubMed PMID: 15668538.
  • Dijkstra A J, Tőke ER, Kolonits P, Recseg K, Kővári K, Poppe L. The Base-Catalysed, Low-Temperature Interesterification Mechanism Revisited, Eur. J. Lipid Sci. Technol., 107, 2005, 912-921.
  • Szatzker G, Pilbák S, Tőke  ER, Bódai  V, Poppe    Enantioselectivity  in Candida antarctica lipase B reaction: transition states calculated by QM/MM methods, 30th FEBS Congress and 9th IUBMB Conference, FEBSJ., 272, 2005, 114, 2-7 july 2005, Budapest, Hungary.
  • Lori F, Lisziewicz J. Hydroxyurea: overview of clinical data and antiretroviral and immunomodulatory Antivir Ther. 1999;4 Suppl 3:101-8. Review. PubMed PMID: 16021881.
  • Kelly LM, Lisziewicz J, Lori F. “Virostatics” as a potential new class of HIV Curr Pharm Des. 2004;10(32):4103-20. Review. PubMed PMID: 15579091.
  • Lisziewicz J, Lori F. 2nd International Symposium on Molecular Diagnostics and Skin Gene Expert Opin Biol Ther. 2003 Jul;3(4):683-7. PubMed PMID: 12831372.
  • Lori F, Kelly LM, Lisziewicz J. Immunological approaches for HIV therapy. Curr Drug TargetsInfect Disord. 2003 Jun;3(2):171-8. Review. PubMed PMID: 12769793.
  • Xu J, Lori F, Lisziewicz J. Vaccinia assay for the rapid detection of functional HIV-specific CD8+ cytotoxic T J Immunol Methods. 2003 May 1;276(1-2):45-57. PubMed PMID: 12738358.
  • Lisziewicz J, Bakare N, Lori F. Therapeutic vaccination for future management of HIV/AIDS. 2003 Jan 30;21(7-8):620-3. Review. PubMed PMID: 12531329.
  • Lori F, Guallini P, Galluzzi L, Lisziewicz J. Gene therapy approaches to HIV Am J Pharmacogenomics. 2002;2(4):245-52. Review. PubMed PMID: 12421095.
  • Xu J, Whitman L, Lori F, Lisziewicz J. Quantification of HIV-specific CD8 T cells by in vitro stimulation with inactivated viral AIDS. 2002 Sep 27;16(14):1849-57. PubMed PMID: 12351944.
  • Lisziewicz J, Lori F. Structured treatment interruptions in HIV/AIDS Microbes Infect. 2002 Feb;4(2):207-14. Review. PubMed PMID: 11880054.
  • Piccinini G, Foli A, Comolli G, Lisziewicz J, Lori F. Complementary antiviral efficacy of hydroxyurea and protease inhibitors in human immunodeficiency virus-infected dendritic cells and J Virol. 2002 Mar;76(5):2274-8. PubMed PMID: 11836405; PubMed Central PMCID: PMC135926.
  • Lori F, Lisziewicz J. Structured treatment interruptions for the management of HIV JAMA. 2001 Dec 19;286(23):2981-7. Review. PubMed PMID: 11743839.
  • Foli A, Benvenuto F, Piccinini G, Bareggi A, Cossarizza A, Lisziewicz J, Lori F. Direct analysis of mitochondrial toxicity of antiretroviral AIDS. 2001 Sep 7;15(13):1687-94. PubMed PMID: 11546944.
  • Jayan GC, Cordelier P, Patel C, BouHamdan M, Johnson RP, Lisziewicz J, Pomerantz RJ, Strayer SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional,and pol III promoters. Gene Ther. 2001 Jul;8(13):1033-42. PubMed PMID: 11438838.
  • Lori F, Lisziewicz J. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus Clin Infect Dis. 2000 Jun;30 Suppl 2:S193-7. Review. PubMed PMID: 10860905.
  • Lisziewicz J, Zeng G, Gratas C, Weinstein JN, Lori F. Combination gene therapy: synergistic inhibition of human immunodeficiency virus Tat and Rev functions by a single RNA Hum Gene Ther. 2000 Apr 10;11(6):807-15. PubMed PMID: 10779158.
  • Lori F, Lisziewicz J. Role of immune modulation in primary HIV J Biol Regul Homeost Agents. 2000 Jan-Mar;14(1):45-8. PubMed PMID: 10763893.
  • Barreio P. and Lori F. The Role of Hydroxyurea in the Treatment of HIV Infection. AIDS Reviews. (2)99-104, 2000.
  • Li Y, Starr SE, Lisziewicz J, Ho Inhibition of HIV-1 replication in chronically infected cell lines and peripheral blood mononuclear cells by retrovirus-mediated antitat gene transfer. Gene Ther. 2000 Feb;7(4):321-8. PubMed PMID: 10694813.
  • Ravot E, Lisziewicz J, Lori F. New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and Drugs. 1999 Dec;58(6):953-63. Review.
  • Lori F. Hydroxyurea for the Therapy of HIV Infection: From Antiviral to Immune-Modulating Effects. The PRN Notebook. 4(2): 9-12, June 4, 1999.
  • Lori F. Hydroxyurea and HIV: 5 Years Later– From Antiviral to Immune-modulating Effects. AIDS. 13(12): 1433-42, 1999. PubMed PMID: 10465065
  • D’Aquila RT, Johnson VA, Lori F, Palmer S. Drug Resistance and Pathogenesis: Clinical Implications of New Data. Massachusetts General Hospital, 1-17, 1999.
  • Foli A. and Lori F. Hydroxyurea Combination Therapy. Journal of HIV Therapy. 4(2): 45-48, 1999.
  • Lori F, Lisziewicz J. Targeting HIV reservoirs and reconstituting the immune Second annual meeting Research Institute for Genetic and Human Therapy April 18-19, 1999 Washington, DC. AIDS Res Hum Retroviruses. 1999 Dec 10;15(18):1597-617. PubMed PMID: 10606083.
  • Lori F, Lisziewicz J. Mechanisms of human immunodeficiency virus type 1 inhibition by J Biol Regul Homeost Agents. 1999 Jul-Sep;13(3):176-80. Review. PubMed PMID: 10560752.
  • Lori F, Lisziewicz J. Cellular factors: targets for the treatment of HIV Antivir Ther. 1998;3 Suppl 4:81-92. PubMed PMID: 10723518.
  • Lori F, Lisziewicz J. Hydroxyurea: mechanisms of HIV-1 Antivir Ther. 1998;3 Suppl 4:25-33. Review. PubMed PMID: 10723506.
  • Lisziewicz J, Sun D, Gallo RC, Ensoli B, Lori F. Efficacy of antitat gene therapy in the presence of high multiplicity infection and inflammatory Hum Gene Ther. 1996 Dec 1;7(18):2209-16. PubMed PMID: 8953311.
  • Yu D, Iyer RP, Shaw DR, Lisziewicz J, Li Y, Jiang Z, Roskey A, Agrawal Hybrid oligonucleotides: synthesis, biophysical properties, stability studies, and biological activity. Bioorg Med Chem. 1996 Oct;4(10):1685-92. PubMed PMID: 8931938.
  • Brother MB, Chang HK, Lisziewicz J, Su D, Murty LC, Ensoli Block of Tat-mediated transactivation of tumor necrosis factor beta gene expression by polymeric-TAR decoys. Virology. 1996 Aug 1;222(1):252-6. PubMed PMID: 8806505.
  • Lisziewicz J. TAR decoys and trans-dominant gag mutant for HIV-1 gene Antibiot Chemother (1971). 1996;48:192-7. Review. PubMed PMID: 8726525.
  • Cara A, Cereseto A, Lori F, Reitz M. HIV-1 Protein Expression from Synthetic Circles of DNA Mimicking the Extrachromosomal Forms of Viral DNA. The Journal of Biological Chemistry 271(10): 5393-5397, 1996. PubMed PMID: 8621393.
  • Weichold FF, Lisziewicz J, Zeman RA, Nerurkar LS, Agrawal S, Reitz MS Jr, Gallo Antisense phosphorothioate oligodeoxynucleotides alter HIV type 1 replication in cultured human macrophages and peripheral blood mononuclear cells. AIDS Res Hum Retroviruses. 1995 Jul;11(7):863-7. PubMed PMID: 7546914.
  • Lisziewicz J, Sun D, Trapnell B, Thomson M, Chang HK, Ensoli B, Peng An autoregulated dual-function antitat gene for human immunodeficiency virus type 1 gene therapy. J Virol. 1995 Jan;69(1):206-12. PubMed PMID: 7983711; PubMed Central PMCID: PMC188565.
  • Lori F, and Gallo RC. Hydroxyurea and AIDS: An Old Drug Finds a New Application? AIDS Res. and Hum. Retr. 11(10): 1149-1151, 1995. PubMed PMID: 8573369
  • Cara A, Guarnaccia F, Reitz MS, Gallo RC, and Lori F. Self-limiting, Cell-type Dependent Replication of an Integrase Defective HIV-1 in Human Macrophages but not in T-lymphocytes. Virology 208:241-248, 1995. PubMed PMID: 11831706
  • Malykh A, Louie A, Hall L, Reitz M, and Lori F. Multiple Hierarchic Determinants for Growth of HIV-1 in Monocyte-macrophage. Virology 206(1): 646-650, 1995. PubMed PMID: 7831820
  • Lori F, Malykh A, Cara A, Sun D, Weinstein JN, Lisziewicz J, Gallo Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science. 1994 Nov 4;266(5186):801-5. PubMed PMID: 7973634.
  • Lisziewicz J, Sun D, Weichold FF, Thierry AR, Lusso P, Tang J, Gallo RC, Agrawal Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells. Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):7942-6. PubMed PMID: 8058738; PubMed Central PMCID: PMC44520.
  • Chang HK, Gendelman R, Lisziewicz J, Gallo RC, Ensoli Block of HIV-1 infection by a combination of antisense tat RNA and TAR decoys: a strategy for control of HIV-1. Gene Ther. 1994 May;1(3):208-16. PubMed PMID: 7584083.
  • Smythe JA, Sun D, Thomson M, Markham PD, Reitz MS Jr, Gallo RC, Lisziewicz J. A Rev- inducible mutant gag gene stably transferred into T lymphocytes: an approach to gene therapy against human immunodeficiency virus type 1 Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3657-61. PubMed PMID: 8170964; PubMed Central PMCID: PMC43640.
  • Lori F, Lisziewicz J, Smythe J, Cara A, Bunnag TA, Curiel D, Gallo Rapid protection against human immunodeficiency virus type 1 (HIV-1) replication mediated by high efficiency non-retroviral delivery of genes interfering with HIV-1 tat and gag. Gene Ther. 1994 Jan;1(1):27-31. PubMed PMID: 7584056.
  • Li G, Lisziewicz J, Sun D, Zon G, Daefler S, Wong-Staal F, Gallo RC, Klotman Inhibition of Rev activity and human immunodeficiency virus type 1 replication by antisense oligodeoxynucleotide phosphorothioate analogs directed against the Rev-responsive element. J Virol. 1993 Nov;67(11):6882-8. PubMed PMID: 8411393; PubMed Central PMCID: PMC238137.
  • Lisziewicz J, Sun D, Smythe J, Lusso P, Lori F, Louie A, Markham P, Rossi J, Reitz M, Gallo Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):8000-4. PubMed PMID: 8367455; PubMed Central PMCID: PMC47275.
  • Lisziewicz J, Sun D, Metelev V, Zamecnik P, Gallo RC, Agrawal Long-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioates. Proc Natl Acad Sci U S A. 1993 May 1;90(9):3860-4. PubMed PMID: 8483903; PubMed Central PMCID: PMC46405.
  • Gao WY, Cara A, Gallo RC, and Lori F. Low Levels of Deoxynucleotides in Peripheral Blood Lymphocytes: A Strategy to Inhibit Human Immunodeficiency Virus Type-1 Replication. Natl. Acad. Sci. USA 90(19): 8925-8928, 1993. PubMed PMCID: PMC47473
  • Zella D, Cavicchini A, Salemi M, Casoli C, Lori F, Achilli G, Cattaneo E, Landini V, and Bertazzoni U. Molecular Characterization of two Isolates of Human T-cell Leukemia Virus Type-II from Italian Drug Abusers and Comparison of Genome Structure with other Isolates. Gen. Virol. 74: 315-319, 1993.
  • Lisziewicz J, Sun D, Klotman M, Agrawal S, Zamecnik P, Gallo Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment. Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11209-13. PubMed PMID: 1454800; PubMed Central PMCID: PMC50519.
  • Lori F, Di Marzo Veronese F, De Vico AL, Lusso P, Reitz MS, and Gallo RC. Viral DNA Carried by HIV-1 Virions. Virol. 66(8): 5067-5074, 1992. PubMed PMCID: PMC241368
  • Lori F, Hall L, Lusso P, Popovic M, Markham P, Franchini G, and Reitz MS, Jr. Effect of Reciprocal Complementation of two Defective Human Immunodeficiency Virus Type- 1 (HIV-1) Molecular Clones on HIV-1 Cell Tropism and Virulence. Virol. 66(9): 5553-5560, 1992. PubMed PMCID: PMC289114.
  • Lisziewicz J, Rappaport J, Dhar Tat-regulated production of multimerized TAR RNA inhibits HIV-1 gene expression. New Biol. 1991 Jan;3(1):82-9. PubMed PMID: 2039768.
  • Lusso P, De Maria A, Malnati M, Lori F, DeRocco SE, Baseler M, and Gallo RC. Induction of CD4 and HIV-1 Susceptibility in Human CD8 + T Lymphocytes by HHV-6. Nature 349(6309): 533- 535, 1991. PubMed PMID: 1846951.
  • Lisziewicz J, Brown J, Breviario D, Sreenath T, Ahmed N, Koller R, Dhar Transcriptional regulatory elements of the RAS2 gene of Saccharomyces cerevisiae. Nucleic Acids Res. 1990 Jul 25;18(14):4167-74. PubMed PMID: 2198534; PubMed Central PMCID: PMC331174.
  • Lusso P, Lori F, and Gallo RC. CD-4 Independent Infection by Human Immunodeficiency Virus Type-1 after Phenotyping Mixing with Human T-cell Leukemia Viruses. Virol. 64(12): 6341-6344, 1990. PubMed PMCID: PMC248817.
  • Zella D, Mori L, Sala M, Ferrante P, Casoli C, Magnani G, Achilli G, Cattaneo E, Lori F, and Bertazzoni U. HTLV-II Infection in Italian Drug Abusers. Lancet 366(8714): 575-576, 1990. PubMed PMID: 1975077.
  • Lori F, Achilli G, Cattaneo E, Casoli C, and Bertazzoni U. Usefulness of Activity Gel Analysis in the Study of Reverse Transcriptase of HIV-1 and other Retroviruses. AIDS Res. 4:1-8, 1990.
  • Agoston DV, Lisziewicz J. Calcium uptake and protein phosphorylation in myenteric neurons, like the release of vasoactive intestinal polypeptide and acetylcholine, are frequency J Neurochem. 1989 May;52(5):1637-40. PubMed PMID: 2540281.
  • Bertazzoni U, Lori F, Achilli G, and Cattaneo E. Assays and Structure of Reverse Transcriptase of the AIDS Virus. Chim. Acta. 183(1): 101-106, 1989.
  • Lisziewicz J, Godany A, Agoston DV, Küntzel Cloning and characterization of the Saccharomyces cerevisiae CDC6 gene. Nucleic Acids Res. 1988 Dec 23;16(24):11507-20. PubMed PMID: 3062576; PubMed Central PMCID: PMC339061.
  • Lori F, Scovassi AI, Zella D, Achilli G, Cattaneo E, Casoli C, and Bertazzoni U. Enzymatically Active Forms of Reverse Transcriptase of the Human Immunodeficiency Virus. AIDS Res. Hum. Retr. 4(5): 393-398, 1988. PubMed PMID:2461725
  • Lori F, Scovassi AI, Brusamolino E, Casoli C, and Starcich R. Different Distribution of DNA Polymerases α and β in Bone Marrow and Peripheral Blood from Human Acute Leukemia. Oncol. Tumor Pharmacother. 5(3): 181-186, 1988. PubMed PMID: 3166085
  • Lori F, Scovassi AI, Brusamolino E, Casoli C, and Starcich R. Different Expression of DNA Polymerase α and β in Bone Marrow and Peripheral Blood in Acute Leukemia. In Habmont, A.C. (Ed.): Attualità in Ematologia, 1987. Bologna, Monduzzi, 1987, pp. 747-750. – Med. Oncol. Pharmacother. 1988; 5 (3): 181-186. PubMed PMID: 3166085.
  • Lisziewicz J, Godany A, Förster HH, Küntzel Isolation and nucleotide sequence of a Saccharomyces cerevisiae protein kinase gene suppressing the cell cycle start mutation cdc25. J Biol Chem. 1987 Feb 25;262(6):2549-53. PubMed PMID: 3546292.
  • Casoli C, Tremolada F, Lori F, Scovassi I, Bertazzoni U, Starcich R, and Alberti A. Reverse Transcriptase Activity in Post-transfusion Non-A Non-B Hepatitis I° Characterization and Association with Retrovirus-like Particles. Serodiagnosis and Immunotherapy 1: 339-346, 1987.
  • Casoli C, Tremolada F, Lori F, Scovassi I, Bertazzoni U, Starcich R, Realdi G, and Alberti A. Detection and Characterization of Reverse Transcriptase Activity in Sera of Patients with Post- transfusion Non-A Non-B Hepatitis. J. Gastroenter.19: 31, 1987.
  • Casoli C, Lori F, and Starcich R. Demontration of the heterogeneity of DNA Polymerase α in Embryonal Tissues with hight proliferative activity: structural analysis of the subunit in the human fetal liver. Soc. It.al Biol. Sper. 62(10): 1205-1211, 1986.
  • Lori F, Casoli C, and Starcich R. DNA Polymerase α Activity in Acute Leukemia: Comparative Analysis of Catalytic Subunits after SDS-PAGE. Boll. Soc. It. Biol. Sper. 62(10): 1197-1203, 1986.
  • Agoston DV, Kosh JW, Lisziewicz J, Whittaker Separation of recycling and reserve synaptic vesicles from cholinergic nerve terminals of the myenteric plexus of guinea pig ileum. J Neurochem. 1985 Jan;44(1):299-305. PubMed PMID: 3964834.
  • Lori F, Casoli C, Albertini R, Bonati A, and Starcich R. Analysis of Catalytic Subunits of DNA Polymerase α in Acute Myeloblastic Leukemia. In Cajozzo, A. and Perricone, R. (Eds.): Attualità in Ematologia. Bologna, Monduzzi, 1985, pp. 120-129.
  • Lori F, Bonati A, Buscaglia M, and Starcich R. The Phenotype of Terminal Deoxynucleotidyl Transferase Positive Cells in the Hemopoietic Tissues of Human Fetuses. In Torelli U, Di Prisco AU, and Castaldini C. (Eds.): Frontiers in Experimental Hematology. Rome, Serono Symposia Publications, 1983, pp. 210-219.